rss
Br J Ophthalmol 2004;88:953-956 doi:10.1136/bjo.2003.032979
  • Laboratory science - Scientific reports

Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension

  1. E D Sharpe1,
  2. D G Day2,
  3. C J Beischel3,
  4. J S Rhodes4,
  5. J A Stewart4,
  6. W C Stewart4,5
  1. 1Ophthalmology Consultants, Mt Pleasant, SC, USA
  2. 2Omni Eye Services, Atlanta, GA, USA
  3. 3Kulze & Beischel, Charleston, SC, USA
  4. 4Pharmaceutical Research Network, LLC, Charleston, SC, USA
  5. 5Carolina Eye Institute at the University of South Carolina School of Medicine, Columbia, SC
  1. Correspondence to: William C Stewart MD Pharmaceutical Research Network, LLC, 1639 Tatum Street, Charleston, SC 29412–2464, USA; prncbellsouth.net
  • Accepted 1 October 2003

Abstract

Background/aims: To evaluate the efficacy of brimonidine purite versus dorzolamide given twice daily in primary open angle glaucoma or ocular hypertensive subjects.

Methods: In this double masked, multicentre, prospective, crossover comparison 33 subjects were randomised to brimonidine purite or dorzolamide for the first 4 week treatment period after a 4 week washout. Subjects began the opposite treatment for the second 4 week period after another 4 week washout. Intraocular pressure (IOP) was measured at 08:00 (trough) and 10:00, 18:00, and 20:00 hours after dosing at each baseline and at the end of each treatment period.

Results: The baseline diurnal IOP was 22.9 (SD 2.8) for brimonidine purite and 22.2 (SD 2.4) mm Hg for dorzolamide. The trough IOP following 4 weeks of therapy was 21.0 (SD 3.7) for brimonidine purite and 21.0 (SD 3.1) mm Hg for dorzolamide (p = 0.90). The mean diurnal IOP was 19.3 (SD 3.1) for brimonidine purite and 19.8 (SD 2.4) mm Hg for dorzolamide (p = 0.46). Dorzolamide caused more ocular stinging upon instillation (n = 8) than brimonidine purite (n = 1) (p = 0.02). No statistical differences existed between groups for systemic adverse events.

Conclusions: This study suggests that brimonidine purite and dorzolamide each given twice daily have similar efficacy in primary open angle glaucoma or ocular hypertensive subjects. However, a trend was observed at 10:00 of greater brimonidine purite efficacy compared with dorzolamide.

Footnotes

  • Supported with an unrestricted grant from Merck, Inc, USA.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.